KMT2A and leukemia: In contrast, a recent study by the Japanese Pediatric Leukemia/Lymphoma Collaborative Group [23] of 43 MLL-r-positive high-risk children (age < 6 months and/or CNS leukemia) who received SCT showed a 3-year EFS and OS of 56.8 and 80.2%, respectively, demonstrating a good prognosis, suggesting that SCT has more therapeutic advantages over conventional chemotherapy.